A Phase 1, Randomized, Placebo Controlled, Blinded (3rd Party Open), Sequential, Multiple-Dose Escalation Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2011
At a glance
- Drugs PF 4878691 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2009 Planned end date changed from 1 Jun 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
- 15 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.